Injection treatment available for reflux in children

Uppsala, Sweden-Q-Med has received FDA approval to market Deflux, a treatmentfor vesicoureteral reflux grades II-IV in children.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria